Lindsy Solanki

Special Counsel
lsolanki@cooley.com
Full contact info

I’m passionate about helping companies navigate the legal environment so that they can create new technologies and transform industries.

About Lindsy

Lindsy represents emerging and high-growth technology and life sciences companies throughout their life cycle, advising on corporate formations, fundraising strategy, private financings, corporate governance, and mergers and acquisitions. She has experience representing late-stage private companies in the initial public offering (IPO) process and advising public companies on US Securities and Exchange Commission (SEC) reporting and follow-on public offerings. She also frequently represents venture capital firms and other investors in corporate financings.

View full bio

Passions

Family

Traveling

Tour de France

Rock Chalk, Jayhawk

Experience

Encord Announces 30 Million Series B

Encord Announces 30 Million Series B

August 13, 2024

Cooley advised Encord, a data development platform for multimodal artificial intelligence, on its $30 million Series B financing.

Read more

Related contacts

Josh Seidenfeld
Partner, Palo Alto
Lindsy Solanki
Special Counsel, Palo Alto
Joseph A. Kroon
Associate, Palo Alto
Christopher Kimball
Partner, Washington, DC
Jonathan Rivinus
Partner, Colorado
John Sellers
Senior Counsel, Palo Alto
Nicola Squire
Partner, London
Christine Graham
Special Counsel, London
Rebecca Ross
Special Counsel, Washington, DC
Sarah Oliai
Associate, Washington, DC
Shelby Saunders
Associate, New York
Kevin Gurley
Quantitative Analyst, New York

Related Practices & Industries

Emerging Companies
Artificial Intelligence
CFIUS
Antitrust and Competition
Tax
Compensation and Benefits

NGM Biopharmaceuticals Announces $122 Million Series A

NGM Biopharmaceuticals Announces $122 Million Series A

July 17, 2024

Cooley advised NGM Biopharmaceuticals (NGM Bio), a wholly owned subsidiary of NGM Bio Holdings and a privately held biotechnology company focused on discovering and developing transformative therapeutics for patients, on its $122 million Series A financing.

Read more

Related contacts

Lauren Creel
Partner, Palo Alto
Chadwick Mills
Partner, San Francisco
Lindsy Solanki
Special Counsel, Palo Alto
Emily Iannarelli
Associate, Palo Alto
Alex Maki
Associate, Palo Alto
Jared Scott Abes
Associate, Palo Alto
Eric Steiner
Paralegal Specialist, San Francisco
Brian Mitchell
Transactional Quantitative Analyst, San Diego
John Sellers
Senior Counsel, Palo Alto

Related Practices & Industries

Emerging Companies
Biotechnology
Healthcare
Life Sciences

Kriya Closes Series C Extension at More Than $150 Million

Kriya Closes Series C Extension at More Than $150 Million

July 26, 2023

Cooley advised Kriya, a biopharmaceutical company, on the close of its Series C extension at more than $150 million in committed and raised capital, bringing the total Series C financing round to more than $430 million.

Related contacts

Lauren Creel
Partner, Palo Alto
Lindsy Solanki
Special Counsel, Palo Alto
Kristina Krasnikova
Associate, Palo Alto
Christopher Kimball
Partner, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Annie Froehlich
Partner, Washington, DC
Zi Ye
Associate, Palo Alto

Related Practices & Industries

Emerging Companies
Venture Capital
Biotechnology

Kriya Announces $270 Million Series C Financing

Kriya Announces $270 Million Series C Financing

May 20, 2022

Cooley advised Kriya Therapeutics, a fully integrated gene therapy company pioneering novel technologies and therapeutics, on its $270 Million Series C financing round. Lawyers Lauren Creel and Lindsy Solanki led the Cooley team advising Kriya.

Read more

Related contacts

Lauren Creel
Partner, Palo Alto
Lindsy Solanki
Special Counsel, Palo Alto
Kristina Krasnikova
Associate, Palo Alto
Sharon Connaughton
Special Counsel, Washington, DC
Annie Froehlich
Partner, Washington, DC
Christopher Kimball
Partner, Washington, DC
Jim Fulton
Partner, New York
Sarah Oliai
Associate, Washington, DC
Josh Seidenfeld
Partner, Palo Alto

Related Practices & Industries

Emerging Companies
Venture Capital
Life Sciences
Biotechnology

Rothy's Enters Strategic Investment Agreement With Alpargatas

Rothy's Enters Strategic Investment Agreement With Alpargatas

December 29, 2021

Cooley advised sustainable lifestyle brand Rothy’s in connection with its strategic investment from Brazilian footwear brand Alpargatas to fuel global growth and expand vertically integrated operations. The transaction will result in a post-investment valuation of $1 billion. Lawyers Jodie Bourdet, Al Browne, Lindsy Solanki, Farzad Tabaee and Meera Patel led the Cooley team advising Rothy’s.

Read more

Related contacts

Jodie Bourdet
Partner, San Francisco
Alfred Browne
Partner, Boston
Lindsy Solanki
Special Counsel, Palo Alto
Farzad Tabaee
Associate, San Francisco
Meera Patel
Associate, San Francisco
Ron Metzger
Paralegal Specialist, San Francisco
Sharon Connaughton
Special Counsel, Washington, DC
Megan Browdie
Partner, Washington, DC
Christopher Kimball
Partner, Washington, DC
Stacey A. Bradford
Special Counsel, Washington, DC
Erica Russell
Associate, San Francisco
Tara Capsuto
Partner, San Francisco
Nicollette R. Kirby
Associate, Washington, DC
Sarah Oliai
Associate, Washington, DC
Addison Pierce
Partner, Chicago

Related Practices & Industries

Fashion, Apparel and Beauty
Retail and Consumer Products
Emerging Companies
Mergers and Acquisitions
Antitrust and Competition
Export Controls and Economic Sanctions
View more

Admissions and credentials

California

Texas

Memberships and affiliations

American Bar Association (ABA)

The State Bar of California

State Bar of Texas